Terumo : Appoints the Candidates for Directors

Press Release

Terumo Appoints the Candidates for Directors

TOKYO, JAPAN - May 14, 2024 - Terumo Corporation (TSE: 4543) hereby announces that it has decided the candidates for directors as below. The elections are subject to the approval of the Annual General Meeting of Shareholders to be held on June 26, 2024.

1. Candidates for directors

(Excluding directors who serve as Audit and Supervisory Committee Members)

Name				New position		Current position
Toshiaki Takagi			Chairman of the Board		Same as on the left
Hikaru Samejima			Representative Director and Chief Executive		Chief Executive Officer
		Officer
Toshihiko Osada			Director and Group Senior Managing Executive		Group Senior Managing
		Officer			Executive Officer
Kazunori Hirose			Director and Group Managing Executive Officer		Same as on the left
Norimasa Kunimoto		Director and Group Managing Executive Officer		Same as on the left
Hidenori Nishi			Independent Director		Same as on the left
Keiya Ozawa			Independent Director		Same as on the left
Mari Kogiso			Independent Director		(New candidate)
2. New Candidate for directors
Hikaru Samejima: Chief Executive Officer
Name						Professional Career
			April 1988	Joined Toa Nenryo Kogyo Corporation (now ENEOS Corporation)
			February 2001	Joined Citi Bank N.A.
Hikaru		January 2002	Joined the Company
	June 2007	President, Terumo Interventional Systems (Global), Cardiac and
Samejima
				Vascular Group
(Born on
	April 2014	Executive Officer
May 27,
				Division President, Interventional Systems Division, Cardiac and
1964)
					Vascular Company
			April 2016	Senior Executive Officer
			April 2017	President, Cardiac and Vascular Company

			April 2018	Managing Executive Officer
			April 2020	President, General Hospital Company (now Medical Care Solutions
				Company)
			April 2022	Group Senior Managing Executive Officer
			April 2024	Chief Executive Officer (current)
Toshihiko Osada: Group Senior Managing Executive Officer
Name				Professional Career
			April 1989	Joined the Company
			January 2016	General Manager, Strategic Planning Department
			April 2016	Executive Officer
			April 2018	Senior Executive Officer
			April 2020	Managing Executive Officer
Toshihiko			President, Cardiac and Vascular Company
Osada			Division President, Interventional Systems Division, Cardiac and
(Born on			Vascular Company
January 28,		April 2022	Group Senior Managing Executive Officer (current)
1967)			April 2024	In charge of Innovation;
				R&D Division (CTO Office, Innovation Center, Technology
				Coordination Office, R&D Administration Department),
				DX Promotion Department, Intellectual Property Department,
				Clinical Development Department, Terumo Medical Pranex
				(current)
Mari Kogiso: Founder and CEO, SDG Impact Japan Inc.
Name				Professional Career
			April 1990	Joined Long-Term Credit Bank of Japan, Limited
			June 1998	Joined World Bank
			June 2003	Representative, Asia, Multilateral Investment Guarantee Agency,
				World Bank Group
Mari Kogiso		October 2012	Founder and CEO, I Incubate Corporation
	October 2014	Representative, Dalberg Japan
(Born on
	January 2016	Head of International Business Planning, Sasakawa Peace
November 15,
		Foundation
1966)
		July 2017	General Manager, Gender Investment and Innovation Division,
				Sasakawa Peace Foundation
			June 2019	General Manager, CEO Office, FAST RETAILING CO., LTD.
			January 2021	Founder and CEO, SDG Impact Japan Inc. (current)
			June 2022	Independent Audit & Supervisory Board Members, Mitsubishi

Corporation (current)

3. Director to resign from the Board Shinjiro Sato

Shoji Hatano Yukiko Kuroda

About Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.